586 results on '"Gordon, M. S."'
Search Results
52. Boxfishes (Teleostei: Ostraciidae) as a model system for fishes swimming with many fins: kinematics
53. Nanojets, Electrospray, and Ion Field Evaporation: Molecular Dynamics Simulations and Laboratory Experiments
54. Evidence of self-correcting spiral flows in swimming boxfishes
55. Giant Piezoresistive On/Off Ratios in Rare-Earth Chalcogenide Thin Films Enabling Nanomechanical Switching
56. Follow-up multicenter alpha counting comparison
57. Ultra-Low Emissivity Alpha-Particle Detection
58. Optical characterization of the Keck array polarimeter at the South Pole
59. The Conversion of a Hybrid Electric Vehicle into a Plug-in Hybrid Electric Vehicle
60. Physical characterization of sub-32-nm semiconductor materials and processes using advanced ion beam-based analytical techniques
61. A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function.
62. Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors.
63. Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors.
64. A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors.
65. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
66. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
67. A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors.
68. First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor.
69. Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function.
70. A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.
71. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a pharmacodynamic (PD) biomarker in phase I trials of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A).
72. Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens.
73. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
74. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.
75. Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer.
76. Sputtering behavior and evolution of depth resolution upon low energy ion irradiation of GaAs
77. ChemInform Abstract: Effect of Hydration and Dimerization of the Formamidine Rearrangement.
78. ChemInform Abstract: Matrix-Infrared Spectra of Structural Isomers of the Phosphorus Oxysulfide P4S3O.
79. ChemInform Abstract: Nature of the Si-N Bond in Silatranes
80. ChemInform Abstract: Predicted Enthalpies of Formation for Methyl-Substituted Silaethylenes and Disilenes.
81. ChemInform Abstract: Hypercoordination in Group IV MH5 and MH- 5 Systems.
82. ChemInform Abstract: Synthesis and Structure of a Tetrasilacyclohexyne.
83. ChemInform Abstract: Ba(Si(OCH2CH2O)3), a Hexaalkoxysilicate Synthesized from Silicon Dioxide
84. ChemInform Abstract: Regiocontrol by Remote Substituents. An Enantioselective Total Synthesis of Frenolicin B via a Highly Regioselective Diels-Alder Reaction.
85. Salmon jumping: behavior, kinematics and optimal conditions, with possible implications for fish passageway design
86. ChemInform Abstract: Direct Total Syntheses of Frenolicin B (VII) and Kalafungin (X) via Highly Regioselective Diels-Alder Reactions.
87. ChemInform Abstract: Effective Core Potential Studies of Transition-Metal Bonding, Structure and Reactivity
88. ChemInform Abstract: More Compelling Evidence That Silicon Is Better than Carbon: The Thermal Isomerization of Olefins to Carbenes
89. ChemInform Abstract: 1,3-Transposition of Allylic Alcohols Catalyzed by Methyltrioxorhenium.
90. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer.
91. Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.
92. Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.
93. Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.
94. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2.
95. An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors.
96. A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.
97. Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.
98. A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).
99. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
100. A phase I study of daily oral TRC102 (methoxyamine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.